Patents by Inventor Michael Frid

Michael Frid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTION
    Publication number: 20230338304
    Abstract: The invention relates to compositions and methods containing hemp and/or cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 26, 2023
    Applicant: VELLA BIOSCIENCE, INC.
    Inventors: Harin Padma-Nathan, MIchael Frid, Helen Segil, Nial Chase DeMena
  • ACIDIC CANNABINOIDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS
    Publication number: 20230321017
    Abstract: The present disclosure provides peripherally acting cannabidiolic acid (CBDA)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form of a topical dosage form, which is applied to female genitalia shortly prior to sexual activity.
    Type: Application
    Filed: March 13, 2023
    Publication date: October 12, 2023
    Inventors: Michael Frid, Harin Padma-Nathan, Nial C. DeMena
  • Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction
    Patent number: 11717495
    Abstract: The invention relates to compositions and methods containing hemp and/or Cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: August 8, 2023
    Assignee: Vella Bioscience, Inc.
    Inventors: Harin Padma-Nathan, MIchael Frid, Helen Segil, Nial Chase DeMena
  • COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY
    Publication number: 20230226061
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent and proliferating cancers cells with DYRK1 inhibitor in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with a MEK inhibitor or a b-RAF inhibitor, or a KRAS inhibitor.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 20, 2023
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Karina Barseguian, Marc Duey
  • PERIPHERALLY ACTING CANNABIDIOL (CBD)-CONTAINING COMPOUNDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS
    Publication number: 20220401381
    Abstract: The present disclosure provides peripherally acting cannabidiol (CBD)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form of a lotion, containing highly CBD-loaded liposomes, which is applied to female genitalia shortly prior to sexual activity.
    Type: Application
    Filed: November 3, 2020
    Publication date: December 22, 2022
    Inventors: Harin Padma-Nathan, Michael Frid
  • LIPOSOMAL FORMULATIONS FOR DELIVERY OF CANNABINOIDS AND METHODS OF MAKING THEREOF
    Publication number: 20220395547
    Abstract: Methods for producing large cannabinoid-loaded liposomes are provided. In one example, these liposomes are large and mostly multilamellar. In another example, the liposomes are a combination of large multilamellar and unilamellar liposomes.
    Type: Application
    Filed: November 3, 2020
    Publication date: December 15, 2022
    Inventors: Michael Frid, Harin Padma-Nathan
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20220110941
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20220110940
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 11202779
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTION
    Publication number: 20210283069
    Abstract: The invention relates to compositions and methods containing hemp and/or cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.
    Type: Application
    Filed: February 2, 2021
    Publication date: September 16, 2021
    Applicant: VELLA BIOSCIENCE, INC.
    Inventors: Harin Padma-Nathan, MIchael Frid, Helen Segil, Nial Chase DeMena
  • Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
    Patent number: 10577365
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 3, 2020
    Assignees: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20190298723
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20190290651
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 10322128
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 18, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
    Patent number: 10314843
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 11, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
    Publication number: 20180179199
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 28, 2018
    Applicants: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20170296542
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20170296541
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • TREATMENT OF CANCER BY TARGETING QUIESCENT CANCER CELLS
    Publication number: 20150292032
    Abstract: A method for treating a subject suffering from a neoplasm, comprising determining the expression level of a DYRK1 selected from DYRK1A or DYRK1B within a cell population in a sample of neoplastic cells and determining the quiescent state of these cells, and if the DYRK1 is expressed in the sample then administering an effective amount of a modulator of DYRK1 activity, either alone or as a part of a combination therapy.
    Type: Application
    Filed: October 10, 2013
    Publication date: October 15, 2015
    Applicant: FELICITEX THERAPEUTICS, INC.
    Inventors: Maria Vilenchik, Michael Frid, Yuri Gankin
  • MIXED AMINAL PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20120295935
    Abstract: Described herein are pharmaceutical compositions for the administration of one or more mixed aminals, as defined herein, including salubrinal and analogs and derivatives of salubrinal, and methods for treating diseases or disorders arising from apoptosis, particularly for treating diseases or disorders arising from integrated stress response-induced apoptosis, such as occurs in bone diseases, injuries, and defects.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 22, 2012
    Inventors: Michael Frid, Kristina M. Hugar